• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » UnDx Consortium to focus on precision medicine

UnDx Consortium to focus on precision medicine

August 16, 2016
CenterWatch Staff

UnDx Consortium has launched. This organization brings together five precision medicine technology providers and experts from medical centers and universities across the country to collaborate in an effort to produce new hypotheses for a set of six patients struggling with undiagnosed diseases. UnDx Consortium will explore results of cutting-edge tests analyzing samples from these patients and their families.

“It has been 13 years since science mapped the human genome, but the promise of personalized medicine remains largely unfulfilled,” said Douglas Jamison, co-organizer of the UnDx Consortium and Chairman of Interome. “Genetics alone is not enough to provide the answers we need. We believe there may be opportunities by applying precision medicine technologies in a multidisciplinary approach that, combined with gene sequencing, will offer new insights on these difficult medical cases.”

The UnDx Consortium is an initiative of precision medicine technology companies and scientists to explore how a multidisciplinary approach to precision medicine can provide information and answers for patients with undiagnosed diseases. The meeting is the beginning of what is expected to evolve into an ongoing forum to explore the potential of combining precision medicine technologies to diagnose and treat disease.

The five technology providers that have donated their services to the UnDx Consortium include:

  • Genome Profiling, of Wilmington, DE, providing epigenetic analysis.
  • The Lab of Rob Knight and the American Gut Project at the University of California San Diego (UCSD), providing microbiome analysis.
  • KromaTiD, of Fort Collins, CO, providing a chromosomal imaging platform for the detection of chromosomal rearrangements.
  • Metabolon, of Durham, NC, providing metabolomic analysis.
  • ORIG3N, of Boston, MA, providing both the sample collection and stem cell analysis.

The main question addressed by the UnDx Consortium is whether the contextual information provided by precision medicine technologies can be used in conjunction with genomic information to provide further hypotheses to the six patients covered in the documentary, Undiagnosed: Medical Refugees, and perhaps become a model to help other undiagnosed patients. The contextual information will complement genomic analyses previously performed in the CLARITY Undiagnosed Challenge, a virtual medical crowdsourcing effort established in conjunction with Boston Children’s and Harvard’s CLARITY Challenge, in an attempt to diagnose five patients whose undiagnosed odyssey was chronicled by the documentary Undiagnosed: Medical Refugees. The CLARITY Undiagnosed Challenge focused on combining the best methods for genomic sequence interpretation with clinical expertise.

The UnDx Consortium resulted from several conversations between Dr. Katia Moritz and Doug Jamison sparked by an early screening of the Undiagnosed documentary at the Strategic News Service Future In Review conference in late 2015. The documentary filmmakers had been collaborating with Dr. Isaac Kohane, principal investigator for the Undiagnosed Diseases Network Coordinating Center, Boston Children’s Hospital’s Manton Center for Orphan Disease Research, the Harvard Medical School’s Center for Biomedical Informatics, and Illumina, to launch a project titled the CLARITY Undiagnosed Challenge.

The UnDx Consortium is sponsored by Interome.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing